Sanofi-Aventis A.E.B.E., a prominent player in the pharmaceutical industry, is headquartered in Greece (GR) and operates extensively across Europe and beyond. Founded in 2004, the company has established itself as a leader in research and development, focusing on innovative healthcare solutions that address unmet medical needs. Sanofi-Aventis is renowned for its diverse portfolio, which includes prescription medicines, vaccines, and consumer healthcare products. Their commitment to quality and innovation sets them apart in a competitive market. With a strong emphasis on therapeutic areas such as diabetes, oncology, and rare diseases, the company has achieved significant milestones, solidifying its position as a trusted name in the healthcare sector.
How does Sanofi-Aventis A.E.B.E.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sanofi-Aventis A.E.B.E.'s score of 100 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sanofi-Aventis A.E.B.E., headquartered in Greece (GR), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sanofi, which cascades its climate commitments and emissions data. Sanofi has set various climate initiatives, including targets under the Science Based Targets initiative (SBTi), and participates in the Carbon Disclosure Project (CDP) and RE100, aiming for 100% renewable electricity. However, specific reduction targets or achievements for Sanofi-Aventis A.E.B.E. are not detailed in the available information. As a subsidiary, Sanofi-Aventis A.E.B.E. aligns with the broader climate strategies of its parent company, Sanofi, which is committed to reducing its carbon footprint across all scopes of emissions. The lack of specific emissions data and reduction targets indicates that further information may be required to assess the subsidiary's individual climate impact and commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 
Sanofi-Aventis A.E.B.E.'s Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sanofi-Aventis A.E.B.E. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.